Effectiveness and Safety of Tofacitinib in Patients With Extensive and Recalcitrant Alopecia Areata
Status:
Completed
Trial end date:
2021-01-30
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess the safety and efficacy of Tofacitinib in treating
patients with extensive and recalcitrant Alopecia Areata (AA), along with to evaluate the
economic impact of the patients that may be from changing in their quality of life. There are
patients with severe AA who may have little or no improvement from the treatment by
diphenylcyclopropenone (DPCP) or topical steroid with minoxidil but instead having positive
response from the treatment with Janus kinase(JAK) inhibitor such as Tofacitinib or
Ruxolitinib. For the best of my knowledge, there was no previous study in using Tofacitinib
to treat severe AA before in Thailand.